Dr. Rajesh Thachathodiyl completed his MBBS and MD (General Medicine) from S.C.B. Medical College Cuttack, Orissa. After specializing in Cardiology from K.M.C. Manipal in 1998, he joined Amrita Institute of Medical Sciences (Amrita Hospital) as faculty in the same year.

Dr. Rajesh has fifteen years of experience in Interventional Cardiology. He has accumulated a wealth of experience and is adept in rotablations, CTO recanalisation, left main interventions, saphenous vein graft interventions, carotid artery interventions, endovascular stent grafts and other peripheral interventions. He has championed the cause of Radial Access Interventions in Amrita and is recognised nationally and internationally in this niche area. Apart from hosting the first 'AMRITA TRANSRADIAL SUMMIT' in Amrita Hospital, Kochi in the year 2008 where Dr. Shigero Saito was the International Faculty, Dr. Rajesh is a regular faculty at the ‘Kamakura Live’ Summit in Japan and the CTO summit in Kobe, Japan. He has also received critical acclaim in the field of ‘Chronic Total Occlusion' and was the national faculty in the INDO - JAPANESE, CTO summit in Mumbai in the year 2013. He has trained a number of young budding cardiologists in radial access complex coronary interventions. Since 2005, Dr. Rajesh has been spearheading the Cardiac CT programme and the Cardiac MRI programme since 2007.

To optimize his PTCA outcomes, Dr. Rajesh regularly uses IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography) and FFR (Fractional Flow Reserve). To add to his repertoire, Dr. Rajesh is also well experienced in permanent pacemaker implantations, automatic implantable cardioverter defibrillator (AICD implantation) and cardiac resynchronisation therapy.

Dr. Rajesh is an avid teacher, has been a DNB examiner in cardiology, and has published papers in journals and authored chapters in a few books. He has undergone interventional training with Dr. Alain Cribbier in Rouen, France; Dr. Jean Fajadet in Toulouse, France; CRT training in Dusseldorf and Milan, Italy; OCT training in Hongkong and renal denervation training in Frankfurt, Germany. Dr. Rajesh is an astute clinican, empathizes with his patients considerably and looks after them well.


Publication Type: Journal Article

Year of Publication Title


A. V. Balegadde, Vijan, V., and Rajesh Thachathodiyl, “A case series of young patients with completely reversed severe pulmonary hypertension”, Journal of Clinical and Diagnostic Research, vol. 11, pp. OR04-OR05, 2017.[Abstract]

Pulmonary Arterial Hypertension (PAH) is a progressive symptomatic disorder, which may ultimately lead to death if left untreated. Although majority of PAH cases are idiopathic, pulmonary hypertension resulting due to certain underlying conditions are also observed frequently. In such cases, it becomes essential to identify any potentially treatable or reversible causes for PAH. There have been significant advances in the medical management of PAH and various medicines have been approved by US Food and Drug Administration (FDA) for various stages of PAH. With these therapies, there can be varying degrees of improvement in the pulmonary artery pressures and hemodynamic profile. Therefore, physiologic reversal can and does occur, sometimes to the point of normalization. We hereby present three such cases of severe PAH in patients below 50 years of age due to various aetiologies like left heart disease, isolated unilateral absence of right pulmonary artery with hypoplastic right lung and factor V Leiden mutation associated pulmonary thromboembolism, all of whose pulmonary artery pressures are completely normalised with adequate treatment of the underlying disease and with optimised medications for PAH, ultimately leading to tapering and stoppage of PAH medications. © 2017, Journal of Clinical and Diagnostic Research. All rights reserved.

More »»


P. Krishnan, Mohan, S., Jom, D., Jacob, R., Joseph, S., Rajesh Thachathodiyl, and Vijan, V., “Comparison of Clinical Effectiveness of Ticagrelor and Clopidogrel in Post Percutaneous Transluminal Coronary Angioplasty (PTCA) Patients Approaching A Tertiary Care Hospital in South India”, Journal of Cardiovascular Disease Research, vol. 7, no. 4, pp. 144-148, 2016.[Abstract]

Introduction: Dual antiplatelet therapy is recommended for prevention of secondary cardiovascular events in acute coronary syndrome patients who undergo percutaneous transluminal coronary angioplasty (PTCA). This therapy includes aspirin with either of a P2Y12 platelet receptor inhibitor like clopidogrel or ticagrelor. Methodology: A retrospective cohort study with 1 year follow up which compared clopidogrel and ticagrelor for determining clinical effectiveness in post PTCA patients through the incidence of primary and secondary end points. Primary end points included cardiovascular death, Myocardial Infarction (MI), unstable angina, secondary revascularization and Congestive Heart Failure (CHF). Secondary end points were bleeding and dyspnea. Results: Age, gender, cardiovascular risk factors, concomitant medications administered and angioplasty specifications like the number of stents, type of stents and approach route were in comparable between clopidogrel and ticagrelor groups. The primary end points, a composite of cardiovascular death, unstable angina and secondary revascularization occurred more in the clopidogrel group (9%) than in ticagrelor group (5%) in 12 months follow up period. The secondary end points, a composite of bleeding and dyspnea were observed more in the ticagrelor group (11%) compared to clopidogrel group (5%). Conclusion: The use of ticagrelor prevents the incidence of secondary cardiovascular events in post PTCA patients to a greater degree than clopidogrel in comparable risk groups. Our observation revealed that ticagrelor was found to be better drug than clopidogrel as a prophylactic antiplatelet drug though there was increased incidence of dyspnea and bleeding in ticagrelor group.

More »»


A. Vupputuri, Vijan, V., Prabhu, M. A., Rajesh Thachathodiyl, and R. Nair, C., “Isolated rheumatic severe tricuspid regurgitation”, Echocardiography, vol. 33, pp. 1769-1770, 2016.[Abstract]

Severe isolated tricuspid regurgitation (TR) is very rare, with most cases of TR being functional and secondary to pulmonary hypertension from left heart pathologies. We report an unusual case of a young Nigerian male, who presented to us with dyspnea, repeated hospital admissions for heart failure, and a childhood history of rheumatic fever. Echocardiogram showed massively dilated right atrium and ventricle, noncoaptation of thickened tricuspid valve with torrential free tricuspid regurgitation. Other valves were normal. Cardiac MRI showed normal right ventricular function and viability. Patient underwent tricuspid valve replacement with 35-mm St. Jude valve. © 2016, Wiley Periodicals, Inc.

More »»